

Claims:

1. A conjugate of Formula (AB) or (AC):



AB



AC

and salts and solvates thereof, wherein:

the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3;

R^2 is independently selected from H, OH, =O, $=CH_2$, CN, R, OR, $=CH\text{-}R^D$, $=C(R^D)_2$, $O\text{-}SO_2\text{-}R$, CO_2R and COR, and optionally further selected from halo or dihalo;

where R^D is independently selected from R, CO_2R, COR, CHO, CO_2H, and halo;

R^6 and R^9 are independently selected from H, R, OH, OR, SH, SR, NH_2, NHR, NRR', NO_2, Me_3Sn and halo;

R^7 is independently selected from H, R, OH, OR, SH, SR, NH_2, NHR, NRR', NO_2, Me_3Sn and halo;

R^{10} is a linker connected to a cell binding agent selected from an antibody, a fragment of an antibody that contains at least one binding site and a cyclic polypeptide;

Q is independently selected from O, S and NH;


R^{11} is either H, or R or, where Q is O, SO_3M, where M is a metal cation;

R and R' are each independently selected from optionally substituted C_{1-12} alkyl, C_{3-20} heterocyclyl and C_{5-20} aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; and

wherein $R^{2"}$, $R^{6"}$, $R^{7"}$, $R^{9"}$, X", Q" and $R^{11"}$ and are as defined according to R^2, R^6, R^7, R^9, X, Q and R^{11} respectively, and R^C is a capping group.

2. The conjugate of claim 1, wherein R^{10} is removable from the N10 position to leave an N10-C11 imine bond.

3. The conjugate of any one of claim 1 or claim 2, wherein R^{10} is a group:



where the asterisk indicates the point of attachment to the N10 position, CBA is a cell binding agent, L^1 is a cleavable linker, A is a connecting group connecting L^1 to the cell binding agent, L^2 is a covalent bond or together with -OC(=O)- forms a self-immolative linker.

4. The conjugate of claim 3, wherein L^1 is enzyme cleavable.

5. The conjugate of claim 3 or claim 4, wherein L^1 comprises a contiguous sequence of amino acids.

6. The conjugate of claim 5, wherein L^1 comprises a dipeptide and the group $-X_1-X_2-$ in dipeptide, -NH-X_1-X_2-CO-, is selected from:

-Phe-Lys-,
-Val-Ala-,
-Val-Lys-,
-Ala-Lys-,
-Val-Cit-,
-Phe-Cit-,
-Leu-Cit-,
-Ile-Cit-,
-Phe-Arg-,
-Trp-Cit-.

Duration: 21.06.2012 09:48:15 - 21.06.2012 09:52:44. This page 3 of 1AMENDED SHEET012 09:49:07
Received at the EPO on Jun 21, 2012 09:52:44. Page 3 of 18

7. The conjugate according to claim 6, wherein the group $-X_1-X_2-$ in dipeptide, $-NH-X_1-X_2-CO-$, is selected from:

-Phe-Lys-,
-Val-Ala-,
-Val-Lys-,
-Ala-Lys-,
-Val-Cit-.


8. The conjugate according to claim 7, wherein the group $-X_1-X_2-$ in dipeptide, $-NH-X_1-X_2-CO-$, is -Phe-Lys-, -Val-Ala- or -Val-Cit-.

9. The conjugate according to any one of claims 6 to 8, wherein the group X_2-CO- is connected to L^2.

10. The conjugate according to any one of claims 6 to 9, wherein the group $NH-X_1-$ is connected to A.

11. The conjugate according to any one of claims 6 to 10, wherein L^2 together with OC(=O) forms a self-immolative linker.

12. The conjugate according to claim 11, wherein C(=O)O and L^2 together form the group:




where the asterisk indicates the point of attachment to the N10 position, the wavy line indicates the point of attachment to the linker L^1, Y is NH, O, C(=O)NH or C(=O)O, and n is 0 to 3.


13. The conjugate according to claim 12, wherein Y is NH.

14. The conjugate according to claim 12 or claim 13, wherein n is 0.

15. The conjugate according to claim 3, wherein L^1 and L^2 together with -OC(=O)- comprise a group selected from:



or




where the asterisk indicates the point of attachment to the N10 position, and the wavy line indicates the point of attachment to the remaining portion of the linker L^1 or the point of attachment to A.

16. The conjugate according to claim 15, wherein the wavy line indicates the point of attachment to A.


17. The conjugate according to any one of claims 3 to 16, wherein A is:

(i)



where the asterisk indicates the point of attachment to L^1, the wavy line indicates the point of attachment to the cell binding agent, and n is 0 to 6; or

(ii)



where the asterisk indicates the point of attachment to L^1, the wavy line indicates the point of attachment to the cell binding agent, n is 0 or 1, and m is 0 to 30.

18. The conjugate according to any one of claims 3 to 17, wherein the cell binding agent is connected to A through a thioether bond formed from a cysteine thiol residue of the cell binding agent and a maleimide group of A.

19. The conjugate according to any one of the preceding claims, wherein the cell binding agent of R^{10} is an antibody or an active fragment thereof.

20. The conjugate according to claim 19, wherein the antibody or antibody fragment is an antibody or antibody fragment for a tumour-associated antigen.

21. The conjugate according to any one of the preceding claims, wherein R^9 is independently H.

22. The conjugate according to any one of the preceding claims, wherein R^6 is independently H.

23. The conjugate according to any one of the preceding claims, wherein R^7 is independently OR^{7A}, where R^{7A} is independently optionally substituted C_{1-4} alkyl.

24. The conjugate of claim 23, wherein R^{7A} is Me.

25. The conjugate according to any one of the preceding claims, wherein X is O.

26. The conjugate according to any one of the preceding claims, wherein R^{11} is H.

27. The conjugate according to any one of the preceding claims, wherein the dotted lines indicate the optional presence of a double bond between C2 and C3.

28. The conjugate according to any one of the preceding claims, wherein R^2 is independently selected from H, =O, $=CH_2$, R, $=CH\text{-}R^D$, and $=C(R^D)_2$.

29. The conjugate according to any one of the preceding claim 28, wherein R^2 is independently $=CH_2$.

June 2012

30. The conjugate according to any one of the preceding claim 28, wherein R^2 is independently R.

31. The conjugate according to any one of the preceding claim 30, wherein R^2 is independently optionally substituted C_{5-20} aryl.


32. The conjugate according to any one of claims 1 to 31, wherein R'' is a C_3 alkylene group or a C_5 alkylene group.

33. The conjugate according to any one of claims 1 to 32, wherein R^C is removable from the N10 position to leave an N10-C11 imine bond.

34. The conjugate according to claim 33, wherein R^C is a carbamate protecting group selected from:

Alloc
Fmoc
Boc
Troc
Teoc
Psec
Cbz
PNZ.

35. The conjugate according to claim 33, wherein R^C is a group:



where the asterisk indicates the point of attachment to the N10 position, G^2 is a terminating group, L^3 is a covalent bond or a cleavable linker L^1, L^2 is a covalent bond or together with OC(=O) forms a self-immolative linker.

36. The conjugate according to claim 35, wherein L^3 is a cleavable linker L^1, and is defined in any one of claims 4 to 9.

June 2012

37. The conjugate according to claim 35 or claim 36, wherein L^2 together with OC(=O) forms a self-immolative linker, and the self-immolative linker is as defined in any one of claims 12 to 14.

38. The conjugate according to any one of claims 35 to 37, wherein G^2 is Ac or Moc, or is a carbamate protecting group selected from:

Alloc
Fmoc
Boc
Troc
Teoc
Psec
Cbz
PNZ.

39. The conjugate according to any one of the preceding claims for use in therapy.

40. The conjugate according to any one of claims 1 to 38, for use in the treatment of a proliferative disease in a subject.

41. The conjugate according to claim 40, wherein the disease is cancer.

42. The conjugate according to according to any one of the preceding claims, having the formula:

$$Ab-(L-D)_p$$

where Ab is an antibody attached by a linker moiety (L) to the formula (AB) or (AC) PBD drug moiety (D), and p is an integer from 1 to about 8.

43. The conjugate of claim 42 wherein Ab is an antibody which binds to one or more tumor-associated antigens or cell-surface receptors selected from (1)-(36):

(1) BMPR1B (bone morphogenetic protein receptor-type IB);
(2) E16 (LAT1, SLC7A5);
(3) STEAP1 (six transmembrane epithelial antigen of prostate);
(4) 0772P (CA125, MUC16);
(5) MPF (MPF, MSLN, SMR, megakaryocyte potentiating factor, mesothelin);

(6) Napi3b (NAPI-3B, NPTIIb, SLC34A2, solute carrier family 34 (sodium phosphate), member 2, type II sodium-dependent phosphate transporter 3b);

(7) Sema 5b (FLJ10372, KIAA1445, Mm.42015, SEMA5B, SEMAG, Semaphorin 5b Hlog, sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B);

(8) PSCA hlg (2700050C12Rik, C530008O16Rik, RIKEN cDNA 2700050C12, RIKEN cDNA 2700050C12 gene);

(9) ETBR (Endothelin type B receptor);

(10) MSG783 (RNF124, hypothetical protein FLJ20315);

(11) STEAP2 (HGNC_8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, prostate cancer associated gene 1, prostate cancer associated protein 1, six transmembrane epithelial antigen of prostate 2, six transmembrane prostate protein);

(12) TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potential cation channel, subfamily M, member 4);

(13) CRIPTO (CR, CR1, CRGF, CRIPTO, TDGF1, teratocarcinoma-derived growth factor);

(14) CD21 (CR2 (Complement receptor 2) or C3DR (C3d/Epstein Barr virus receptor) or Hs 73792);

(15) CD79b (CD79B, CD79β, IGb (immunoglobulin-associated beta), B29);

(16) FcRH2 (IFGP4, IRTA4, SPAP1A (SH2 domain containing phosphatase anchor protein 1a), SPAP1B, SPAP1C);

(17) HER2;

(18) NCA;

(19) MDP;

(20) IL20Rα;

(21) Brevican;

(22) EphB2R;

(23) ASLG659;

(24) PSCA;

(25) GEDA;

(26) BAFF-R (B cell -activating factor receptor, BLyS receptor 3, BR3);

(27) CD22 (B-cell receptor CD22-B isoform);

(28) CD79a (CD79A, CD79α, immunoglobulin-associated alpha);

(29) CXCR5 (Burkitt's lymphoma receptor 1);

(30) HLA-DOB (Beta subunit of MHC class II molecule (Ia antigen));

(31) P2X5 (Purinergic receptor P2X ligand-gated ion channel 5);

(32) CD72 (B-cell differentiation antigen CD72, Lyb-2);

(33) LY64 (Lymphocyte antigen 64 (RP105), type I membrane protein of the leucine rich repeat (LRR) family);

(34) FcRH1 (Fc receptor-like protein 1);

(35) IRTA2 (Immunoglobulin superfamily receptor translocation associated 2); and

(36) TENB2 (putative transmembrane proteoglycan).

44. The conjugate of claim 42 wherein Ab is a cysteine-engineered antibody.

45. The conjugate of either claim 42 or claim 43 wherein Ab is an antibody which binds to an ErbB receptor.


46. The conjugate of claim 45 wherein Ab is trastuzumab.

47. The conjugate of either claim 42 or claim 43 wherein Ab is an anti-HER2, an anti-Steap1, or an anti-CD22 antibody.

48. The conjugate of any one of claims 42 to 47 wherein p is 1, 2, 3, or 4.


49. The conjugate of any one of claims 42 to 48 comprising a mixture of the antibody-drug conjugate compounds, wherein the average drug loading per antibody in the mixture of antibody-drug conjugate compounds is about 2 to about 5.


50. The conjugate of any one of claims 42 to 49 having a formula selected from:





June 2012

223










and

June 2012



where n is an integer from 1 to 24.

51. The conjugate of claim 50, where n is an integer from 1 to 12.

52. The conjugate of claim 51, where n is 4 or 8.

53. A pharmaceutical composition comprising the conjugate of any one of claims 1 to 52 a pharmaceutically acceptable diluent, carrier or excipient.


54. The pharmaceutical composition of claim 53 further comprising a therapeutically effective amount of a chemotherapeutic agent.

55. Use of a conjugate according to any one of claims 1 to 52 in the preparation of a medicament for use in the treatment of a proliferative disease in a subject.

56. A method of treating cancer comprising administering to a patient the pharmaceutical composition of claim 53.

57. The method of claim 56 wherein the patient is administered a chemotherapeutic agent, in combination with the conjugate.

58. Use of a conjugate according to any one of claims 1 to 52 to provide a compound of formula (CA) at a target location:



CA

and salts and solvates thereof, wherein:

the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3;

R^2 is independently selected from H, OH, =O, $=CH_2$, CN, R, OR, $=CH\text{-}R^D$, $=C(R^D)_2$, $O\text{-}SO_2\text{-}R$, CO_2R and COR, and optionally further selected from halo or dihalo;

where R^D is independently selected from R, CO_2R, COR, CHO, CO_2H, and halo;

R^6 and R^9 are independently selected from H, R, OH, OR, SH, SR, NH_2, NHR, NRR', NO_2, Me_3Sn and halo;

R^7 is independently selected from H, R, OH, OR, SH, SR, NH_2, NHR, NRR', NO_2, Me_3Sn and halo;

R and R' are each independently selected from optionally substituted C_{1-12} alkyl, C_{3-20} heterocyclyl and C_{5-20} aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;

R'' is a C_{3-12} alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, N(H), NMe and/or aromatic rings, e.g. benzene or pyridine, which rings are optionally substituted by NH_2;


each X is O, S or N(H); and

wherein R^{2*}, R^{6*}, R^{7*}, R^{9*}, and X'' are as defined according to R^2, R^6, R^7, R^9, and X respectively.

59. The use according to claim 58, wherein the target location is a proliferative cell population.

Duration: 21.06.2012 09:48:15 - 21.06.2012 09:52:44. This page 13 of AMENDED SHEET 2012 09:51:33
Received at the EPO on Jun 21, 2012 09:52:44. Page 13 of 18
12/17 21-06-2012

60. Use of a conjugate according to any one of claims 1 to 52 to provide a compound of formula (DA) at a target location:



DA

and salts and solvates thereof, wherein:

the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3;

R^2 is independently selected from H, OH, =O, $=CH_2$, CN, R, OR, $=CH\text{-}R^D$, $=C(R^D)_2$, $O\text{-}SO_2\text{-}R$, CO_2R and COR, and optionally further selected from halo or dihalo;

where R^D is independently selected from R, CO_2R, COR, CHO, CO_2H, and halo;

R^6 and R^9 are independently selected from H, R, OH, OR, SH, SR, NH_2, NHR, NRR', NO_2, Me_3Sn and halo;

R^7 is independently selected from H, R, OH, OR, SH, SR, NH_2, NHR, NRR', NO_2, Me_3Sn and halo;

Q is independently selected from O, S and NH;

R^{11} is either H, or R or, where Q is O, R^{11} is SO_3M, where M is a metal cation;

R and R' are each independently selected from optionally substituted C_{1-12} alkyl, C_{3-20} heterocyclyl and C_{5-20} aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;


R" is a C_{3-12} alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, N(H), NMe and/or aromatic rings, e.g. benzene or pyridine, which rings are optionally substituted by NH_2;

each X is O, S or N(H); and


wherein $R^{2"}$, $R^{6"}$, $R^{7"}$, $R^{9"}$, Q", $R^{11"}$ and X" are as defined according to R^2, R^6, R^7, R^9, Q, R^{11} and X respectively.

Duration: 21.06.2012 09:48:15 - 21.06.2012 09:52:44. This page 14 of AMENDED SHEET 2012 09:51:50
Received at the EPO on Jun 21, 2012 09:52:44. Page 14 of 18

61. A compound of formula (EB) or (EC):



EB



EC

and salts and solvates thereof, wherein

the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3;

R^2 is independently selected from H, OH, =O, $=CH_2$, CN, R, OR, $=CH\text{-}R^D$, $=C(R^D)_2$, $O\text{-}SO_2\text{-}R$, CO_2R and COR, and optionally further selected from halo or dihalo;

where R^D is independently selected from R, CO_2R, COR, CHO, CO_2H, and halo;

R^9 and R^9 are independently selected from H, R, OH, OR, SH, SR, NH_2, NHR, NRR', NO_2, Me_3Sn and halo;

R^7 is independently selected from H, R, OH, OR, SH, SR, NH_2, NHR, NRR', NO_2, Me_3Sn and halo;

R^L is a linker for connection to a cell binding agent selected from an antibody, a fragment of an antibody that contains at least one binding site and a cyclic polypeptide;

Q is independently selected from O, S and NH;

R^{11} is either H, or R or, where Q is O, R^{11} is SO_3M, where M is a metal cation;


R and R' are each independently selected from optionally substituted C_{1-12} alkyl, C_{3-20} heterocyclyl and C_{5-20} aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;

R" is a C_{3-12} alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, N(H), NMe and/or aromatic rings, e.g. benzene or pyridine, which rings are optionally substituted by NH_2;

each X is O, S or N(H); and

wherein $R^{2'}$, $R^{6'}$, $R^{7'}$, $R^{9'}$, $R^{11'}$, Q' and X' are as defined according to R^2, R^6, R^7, R^9, R^{11}, Q and X respectively, and R^C is a capping group.

62. The compound of claim 61 having the structure:




where n is an integer from 1 to 24.

63. The compound of claim 62, where n is an integer from 1 to 12.

64. The compound of claim 63 where n is 4 or 8.

65. The compound of claim 61 having the structure:




where n is an integer from 1 to 24.

66. The compound of claim 65 where n is an integer from 1 to 12.

67. The compound of claim 66 where n is 4 or 8.

June 2012

68. The compound of claim 61 having the structure:





where n is an integer from 1 to 24.

69. The compound of claim 68 where n is an integer from 1 to 12.


70. The compound of claim 69 where n is 4 or 8.

71. The compound of claim 61, which is selected from:

(i)  ;

(ii)  ; and

ation: 21.06.2012 09:48:15 - 21.06.2012 09:52:44. This page 17 of AMENDED SHEET 2012 09:52:31
Received at the EPO on Jun 21, 2012 09:52:44. Page 17 of 18

(iii) 


72. A method of preparing a conjugate according to any one of claims 1 to 52, the method comprising the step of reacting a cell binding agent with compound (EB) or (EC) as defined in any one of claims 61 to 71.

73. An article of manufacture comprising a pharmaceutical composition of claim 53; a container; and a package insert or label indicating that the pharmaceutical composition can be used to treat cancer.


uration: 21.06.2012 09:48:15 - 21.06.2012 09:52:44. This page 18 of AMENDED SHEET 2012 09:52:44
Received at the EPO on Jun 21, 2012 09:52:44. Page 18 of 18

Claims:

1. A conjugate of Formula (AB) or (AC):



AB



AC

and salts and solvates thereof, wherein:

the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3;

R^2 is independently selected from H, OH, =O, $=CH_2$, CN, R, OR, $=CH\text{-}R^D$, $=C(R^D)_2$, $O\text{-}SO_2\text{-}R$, CO_2R and COR, and optionally further selected from halo or dihalo;

where R^D is independently selected from R, CO_2R, COR, CHO, CO_2H, and halo;

R^6 and R^9 are independently selected from H, R, OH, OR, SH, SR, NH_2, NHR, NRR', NO_2, Me_3Sn and halo;

R^7 is independently selected from H, R, OH, OR, SH, SR, NH_2, NHR, NRR', NO_2, Me_3Sn and halo;

R^{10} is a linker connected to a cell binding agent selected from an antibody, a fragment of an antibody that contains at least one binding site and a cyclic polypeptide;

Q is independently selected from O, S and NH;

R^{11} is either H, or R or, where Q is O, SO_3M, where M is a metal cation;


R and R' are each independently selected from optionally substituted $C_{1\text{-}12}$ alkyl, $C_{3\text{-}20}$ heterocyclyl and $C_{5\text{-}20}$ aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;

R'' is a $C_{3\text{-}12}$ alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, N(H), NMe and/or aromatic rings, e.g. benzene or pyridine, which rings are optionally substituted by NH_2;

each X is O, S or N(H); and

wherein $R^{2"}$, $R^{6"}$, $R^{7"}$, $R^{9"}$, X", Q" and $R^{11"}$ are as defined according to R^2, R^6, R^7, R^9, X, Q and R^{11} respectively, and R^C is a capping group.

2. The conjugate of claim 1, wherein R^{10} is a group:



where the asterisk indicates the point of attachment to the N10 position, CBA is the cell binding agent, L^1 is a cleavable linker, A is a connecting group connecting L^1 to the cell binding agent, L^2 is a covalent bond or together with -OC(=O)- forms a self-immolative linker.

3. The conjugate of claim 2, wherein L^1 is enzyme cleavable.

4. The conjugate of claim 3, wherein L^1 comprises a dipeptide and the group $-X_1-X_2-$ in the dipeptide, $-NH-X_1-X_2-CO-$, is selected from:


-Phe-Lys-,
-Val-Ala-,
-Val-Lys-,
-Ala-Lys-,
-Val-Cit-,
-Phe-Cit-,
-Leu-Cit-,
-Ile-Cit-,
-Phe-Arg-,
-Trp-Cit-.

5. The conjugate according to claim 4, wherein the group $-X_1-X_2-$ in the dipeptide, $-NH-X_1-X_2-CO-$, is -Phe-Lys-, -Val-Ala- or -Val-Cit-.

6. The conjugate according to either claim 4 or claim 5, wherein the group X_2-CO- is connected to L^2, and the group $NH-X_1-$ is connected to A.

7. The conjugate according to any one of claims 4 to 6, wherein L^2 together with OC(=O) forms a self-immolative linker.


8. The conjugate according to claim 7, wherein C(=O)O and L^2 together form the group:




where the asterisk indicates the point of attachment to the N10 position, the wavy line indicates the point of attachment to the linker L^1, Y is NH, O, C(=O)NH or C(=O)O, and n is 0 to 3.

9. The conjugate according to claim 8, wherein Y is NH, and n is 0.

10. The conjugate according to claim 2, wherein L^1 and L^2 together with -OC(=O)- comprise a group selected from:




or



where the asterisk indicates the point of attachment to the N10 position, and the wavy line indicates the point of attachment to A.


11. The conjugate according to any one of claims 2 to 10, wherein A is:

(i)



where the asterisk indicates the point of attachment to L^1, the wavy line indicates the point of attachment to the cell binding agent, and n is 0 to 6; or

(ii)



where the asterisk indicates the point of attachment to L^1, the wavy line indicates the point of attachment to the cell binding agent, n is 0 or 1, and m is 0 to 30.

12. The conjugate according to any one of claims 2 to 11, wherein the cell binding agent is connected to A through a thioether bond formed from a cysteine thiol residue of the cell binding agent and a malemide group of A.

13. The conjugate according to any one of the preceding claims, wherein the cell binding agent of R^{10} is an antibody or an active fragment thereof.

14. The conjugate according to claim 13, wherein the antibody or antibody fragment is an antibody or antibody fragment for a tumour-associated antigen.

15. The conjugate according to any one of the preceding claims, wherein R^9 is independently H and R^6 is independently H.

16. The conjugate according to any one of the preceding claims, wherein R^7 is independently OMe.

17. The conjugate according to any one of the preceding claims, wherein X is O.

18. The conjugate according to any one of the preceding claims, wherein R^{11} is H.

19. The conjugate according to any one of the preceding claims, wherein the dotted lines indicate the optional presence of a double bond between C2 and C3.

20. The conjugate according to any one of the preceding claims, wherein R^2 is independently selected from H, =O, $=CH_2$, R, $=CH\text{-}R^D$, and $=C(R^D)_2$.

21. The conjugate according to claim 20, wherein R^2 is independently $=CH_2$.

22. The conjugate according to claim 20, wherein R^2 is independently optionally substituted $C_{5\text{-}20}$ aryl.


23. The conjugate according to any one of claims 1 to 22, wherein R'' is a C_3 alkylene group or a C_5 alkylene group.

24. The conjugate according to any one of claims 1 to 23, wherein R^C is removable from the N10 position to leave an N10-C11 imine bond.

25. The conjugate according to claim 24, wherein R^C is a carbamate protecting group selected from:

Alloc
Fmoc
Boc
Troc
Teoc
Psec
Cbz
PNZ.

26. The conjugate according to claim 24, wherein R^C is a group:



where the asterisk indicates the point of attachment to the N10 position, G^2 is a terminating group, L^3 is a covalent bond or a cleavable linker L^1, L^2 is a covalent bond or together with OC(=O) forms a self-immolative linker.

27. The conjugate according to claim 26, wherein L^3 is a cleavable linker L^1, and is defined in any one of claims 3 to 6.

28. The conjugate according to claim 26 or claim 27, wherein L^2 together with OC(=O) forms a self-immolative linker, and the self-immolative linker is as defined in either claim 8 or 9.

29. The conjugate according to any one of claims 26 to 28, wherein G^2 is Ac or Moc, or is a carbamate protecting group selected from:

Alloc
Fmoc
Boc
Troc
Teoc
Psec
Cbz
PNZ.

30. The conjugate according to any one of the preceding claims for use in therapy.

31. The conjugate according to any one of claims 1 to 29, for use in the treatment of a proliferative disease in a subject, wherein the disease is cancer.

32. A conjugate having the formula:

$$Ab–(L–D)_p$$

where Ab is an antibody attached by a linker moiety (L) to the formula (AB) or (AC) PBD drug moiety (D), and p is an integer from 1 to about 8, wherein the linker moiety (L) and the PBD drug moiety (D) of formula (AB) or (AC) as defined in any one of claims 1 to 29.

33. The conjugate of claim 32 wherein Ab is an antibody which binds to one or more tumor-associated antigens or cell-surface receptors selected from (1)-(36):

(1) BMPR1B (bone morphogenetic protein receptor-type IB);

(2) E16 (LAT1, SLC7A5);

(3) STEAP1 (six transmembrane epithelial antigen of prostate);

(4) 0772P (CA125, MUC16);

(5) MPF (MPF, MSLN, SMR, megakaryocyte potentiating factor, mesothelin);

(6) Napi3b (NAPI-3B, NPTIIb, SLC34A2, solute carrier family 34 (sodium phosphate), member 2, type II sodium-dependent phosphate transporter 3b);

(7) Sema 5b (FLJ10372, KIAA1445, Mm.42015, SEMA5B, SEMAG, Semaphorin 5b Hlog, sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B);

(8) PSCA hlg (2700050C12Rik, C530008O16Rik, RIKEN cDNA 2700050C12, RIKEN cDNA 2700050C12 gene);

(9) ETBR (Endothelin type B receptor);

(10) MSG783 (RNF124, hypothetical protein FLJ20315);

(11) STEAP2 (HGNC_8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, prostate cancer associated gene 1, prostate cancer associated protein 1, six transmembrane epithelial antigen of prostate 2, six transmembrane prostate protein);

(12) TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potential cation channel, subfamily M, member 4);

(13) CRIPTO (CR, CR1, CRGF, CRIPTO, TDGF1, teratocarcinoma-derived growth factor);

(14) CD21 (CR2 (Complement receptor 2) or C3DR (C3d/Epstein Barr virus receptor) or Hs 73792);

(15) CD79b (CD79B, CD79β, IGb (immunoglobulin-associated beta), B29);

(16) FcRH2 (IFGP4, IRTA4, SPAP1A (SH2 domain containing phosphatase anchor protein 1a), SPAP1B, SPAP1C);

(17) HER2;

(18) NCA;

(19) MDP;

(20) IL20Rα;

(21) Brevican;

(22) EphB2R;

(23) ASLG659;

(24) PSCA;

(25) GEDA;

(26) BAFF-R (B cell -activating factor receptor, BLyS receptor 3, BR3);

(27) CD22 (B-cell receptor CD22-B isoform);

(28) CD79a (CD79A, CD79α, immunoglobulin-associated alpha);

(29) CXCR5 (Burkitt's lymphoma receptor 1);

(30) HLA-DOB (Beta subunit of MHC class II molecule (Ia antigen));

(31) P2X5 (Purinergic receptor P2X ligand-gated ion channel 5);

(32) CD72 (B-cell differentiation antigen CD72, Lyb-2);

(33) LY64 (Lymphocyte antigen 64 (RP105), type I membrane protein of the leucine rich repeat (LRR) family);

(34) FcRH1 (Fc receptor-like protein 1);

(35) IRTA2 (Immunoglobulin superfamily receptor translocation associated 2); and

(36) TENB2 (putative transmembrane proteoglycan).

34. The conjugate of claim 32 wherein Ab is a cysteine-engineered antibody.


35. The conjugate of either claim 32 or claim 33 wherein Ab is an antibody which binds to an ErbB receptor.


36. The conjugate of claim 35 wherein Ab is trastuzumab.


37. The conjugate of either claim 32 or claim 33 wherein Ab is an anti-HER2, an anti-Steap1, or an anti-CD22 antibody.


38. The conjugate of any one of claims 32 to 37 wherein p is 1, 2, 3, or 4.


39. The conjugate of any one of claims 32 to 38 having a formula selected from:












and



where n is an integer from 1 to 24.

40. The conjugate of claim 39, where n is an integer from 1 to 12.


41. The conjugate of claim 40, where n is 4 or 8.

42. A pharmaceutical composition comprising the conjugate of any one of claims 1 to 29 or claims 32 to 41 a pharmaceutically acceptable diluent, carrier or excipient.


43. The pharmaceutical composition of claim 42 further comprising a therapeutically effective amount of a chemotherapeutic agent.

44. Use of a conjugate according to any one of claims 1 to 29 or claims 32 to 41 in the preparation of a medicament for use in the treatment of a proliferative disease in a subject.

45. A compound of formula (EB) or (EC):



EB



EC

and salts and solvates thereof, wherein

the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3;

R^2 is independently selected from H, OH, =O, $=CH_2$, CN, R, OR, $=CH\text{-}R^D$, $=C(R^D)_2$, $O\text{-}SO_2\text{-}R$, CO_2R and COR, and optionally further selected from halo or dihalo;

where R^D is independently selected from R, CO_2R, COR, CHO, CO_2H, and halo;

R^6 and R^9 are independently selected from H, R, OH, OR, SH, SR, NH_2, NHR, NRR', NO_2, Me_3Sn and halo;

R^7 is independently selected from H, R, OH, OR, SH, SR, NH_2, NHR, NRR', NO_2, Me_3Sn and halo;

R^L is a linker for connection to a cell binding agent selected from an antibody, a fragment of an antibody that contains at least one binding site and a cyclic polypeptide;

Q is independently selected from O, S and NH;

R^{11} is either H, or R or, where Q is O, R^{11} is SO_3M, where M is a metal cation;

R and R' are each independently selected from optionally substituted C_{1-12} alkyl, C_{3-20} heterocyclyl and C_{5-20} aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;


R'' is a C_{3-12} alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, N(H), NMe and/or aromatic rings, e.g. benzene or pyridine, which rings are optionally substituted by NH_2;

each X is O, S or N(H); and


wherein $R^{2"}$, $R^{6"}$, $R^{7"}$, $R^{9"}$, $R^{11"}$, Q" and X" are as defined according to R^2, R^6, R^7, R^9, R^{11}, Q and X respectively, and R^C is a capping group;

wherein R^L is different to R^C.


46. The compound of claim 45 having the structure:



;



; or





where n is an integer from 1 to 24.


47. The compound of claim 46 where n is an integer from 1 to 12.

48. The compound of claim 47 where n is 4 or 8.

49. The compound of claim 45, which is selected from:

(i) ;

(ii) ; and

(iii) .